A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

Phase 2

Recruiting

• Conditions: Vitiligo
• Interventions: Drug: Afamelanotide

• Registration Number: NCT05210582
• Lead Sponsor: Clinuvel, Inc.

Brief Summary

The CUV104 study will assess the efficacy and safety of afamelanotide in patients with vitiligo on the face and body as a monotherapy in repigmentation.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-01-11
• Study First Submitted QC: 2022-01-11
• Study First Posted: 2022-01-27
• Study Start: 2022-10-11
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-07
• Last Update Posted: 2023-02-09
• Primary Completion: 2023-04
• Study Completion: 2023-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

• Male and female patients with a confirmed diagnosis of vitiligo on the face and with T-VASI range 0.5-50%
• Stable face vitiligo with F-VASI of at least 0.1%
• Stable or slowly progressive vitiligo over a 3-month period
• Fitzpatrick skin types IV-VI
• Treatment with narrowband (NB)-UVB light 2-3 times per week during the last four weeks preceding the first implant for priming

Exclusion Criteria

• Patients with segmental vitiligo
• Fitzpatrick skin types I-III
• Treatment with NB-UVB phototherapy in the last three months prior to phototherapy, excluding the sessions for priming in the four weeks prior to treatment. A 3-month washout period from phototherapy is necessary prior to priming.
• Previous topical treatment for vitiligo
• Allergy to afamelanotide or the polymer contained in the implant or to lignocaine/lidocaine or other local anaesthetic to be used during the administration of the implant
• History of melanoma or lentigo maligna
• Any current skin disease that may interfere with the study evaluation
• Presence of severe hepatic disease or hepatic impairment
• Renal impairment
• History of systemic or psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation
• Female who is pregnant or lactating
• Female of child-bearing potential not using adequate contraceptive measures during the treatment phase and for a period of three months thereafter
• Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures, as described above
• Participation in a clinical trial for an investigational agent within 30 days prior to the Screening Visit
• Use of any other prior and concomitant therapy which may interfere with the objective of the study
• Subjects assessed as not suitable for the study in the opinion of the Investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Afamelanotide	Afamelanotide	-

Primary Outcome Measures

Name	Time	Method
Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on facial lesions	From Baseline to Day 84	Measured using Vitiligo Area Scoring Index (VASI). A decrease in VASI indicates a reduction of the facial surface area affected by vitiligo (possible range 1-100)

Secondary Outcome Measures

Name	Time	Method
Proportion of participants achieving Vitiligo Area Scoring Index (VASI)25 on body surface area	From Baseline to Day 84	Proportion of participants achieving VASI25 on body surface area (excluding hands and feet). A decrease in VASI indicates a reduction of the facial surface area affected by vitiligo (possible range 1-100).
Change in Quality of life using a vitiligo specific tool (C)	From Baseline to Day 168	Higher value means a lower quality of life
Percentage change in pigmentation on body surface area measured by the VASI scoring system	From Baseline to Day 84	Percentage change in pigmentation on body surface area (excluding hands and feet) measured by VASI scoring system. A decrease in VASI indicates a reduction of the body surface area affected by vitiligo (possible range 1-100)
Percentage change in pigmentation on facial surface area measured by the VASI scoring system	From Baseline to Day 168	A decreased VASI indicates a reduction in the faces' degree of depigmentation (possible range 1-100)
Change in Perception of Vitiligo Severity using a vitiligo validated specific tool (A)	From Baseline to Day 168	The higher the score, the more severe the disease
Change in Noticeability of Vitiligo using a vitiligo validated specific tool (B)	From Baseline to Day 168	Higher the value means lower noticeability

Trial Locations

Locations (1)

CLINUVEL Investigational site; 🇺🇸 Detroit, Michigan, United States